The market for non-steroidal anti-inflammatory and antirheumatic medicines in Spain has experienced a varied trajectory over the last decade. Between 2013 and 2020, there was a consistent decline in sales value, marked by the most significant drop in 2015 with a 26.5% decrease. The decline plateaued somewhat in 2020 with more moderate fluctuations. Starting from 2021, the market began to show signs of recovery, with a notable 14.94% rise in sales. By 2023, sales had risen to 278.4 million USD, reflecting a 2.73% increase from the previous year.
Looking ahead, forecast data suggest a continued, albeit moderate, growth in the market. From 2024 to 2028, sales are expected to rise steadily from 284.6 million USD to 299.1 million USD, translating to a 5.09% growth rate over five years and an average annual growth rate (CAGR) of approximately 1%.
Future trends to watch:
- Potential impacts of new regulatory policies on market dynamics.
- Introduction of new treatment alternatives and their effects on market share.
- Economic factors influencing healthcare spending in Spain.
- Technological advancements in drug formulations and delivery methods.
- Potential shifts in consumer preferences and behaviors towards non-steroidal anti-inflammatory drugs.
